Analyst lowers TransMedics Group target amid stable MedTech sector trends while company expands European organ transplant logistics.
Evercore ISI analyst Daniel Markowitz reduced the price target on TransMedics Group (NASDAQ:TMDX) to $90 from $100, maintaining an Outperform rating. The adjustment reflects the firm’s second-quarter outlook for MedTech, Life Sciences Tools, and Diagnostics sectors, citing stable procedure volumes and capital spending trends.
The revised target follows TMDX’s announcement of a strategic investment in PAD Aviation to expand its Organ Care System into Europe. The partnership aims to enhance organ transportation logistics and increase transplant opportunities across the EU, reinforcing the company’s international infrastructure strategy.
Shares of TMDX were not immediately impacted by the target cut or the strategic investment announcement, as broader sector stability was noted in the analyst’s research.